Regulatory Strategy for SaMD Registration in the US
The U.S. SaMD landscape is evolving quickly as AI-enabled clinical decision support, remote monitoring, and software-driven diagnostics become mainstream. FDA’s digital health focus increasingly emphasizes a total product lifecycle mindset, where premarket decisions connect directly to real-world performance monitoring, cybersecurity resilience, and disciplined software change control. Recent FDA SaMD requirements also signal heightened expectations for how SaMD developers document intended use, evidence, and risk controls.
For MedTech and digital health manufacturers, the opportunity is clear. The U.S. remains one of the most scalable markets for software-led care. The challenge is translating innovation into a submission-ready pathway, selecting 510(k), De Novo, or PMA routes, preparing consistent technical documentation, and anticipating post-market obligations for updates, complaints, and cybersecurity, including requirements tied to “cyber devices.” Missteps in classification, clinical evidence planning, or change management commonly create avoidable delays.
Freyr helps organizations navigate this complexity with a practical, risk-based Regulatory strategy that aligns product intent, evidence, quality management system for SaMD readiness, and cybersecurity planning into one coherent U.S. pathway. We support pre-submission planning through submission execution and post-market lifecycle governance, helping teams stay compliant as software and expectations continue to evolve.
Digital Health & SaMD Regulatory Services for US
Our regulatory services are designed to support your digital health SaMD product across its entire lifecycle, from early planning through commercialization and post-market compliance.
![]()
Regulatory Strategy & Planning
Customized FDA SaMD regulatory roadmaps aligned to your product’s risk classification, intended use, and US market entry goals.
![]()
FDA Premarket Submissions
End-to-end support for 510(k), De Novo, and PMA submissions, including documentation preparation, FDA interactions, and submission follow-up.
![]()
Quality & Compliance Support
Guidance on FDA Quality Management System for SaMD requirements, software lifecycle controls, cybersecurity expectations, and ongoing regulatory obligations
![]()
Post-Market Support
Assistance with post-market surveillance, adverse event reporting, software updates, and sustained FDA SaMD compliance.
![]()
Consulting & Advisory
Expert regulatory guidance on pathway selection, risk management, and best practices for FDA SaMD classification and digital health innovation.
With Freyr’s expertise, you can confidently navigate the US regulatory landscape, SaMD registrations in US, reduce time-to-market and ensure sustained compliance for your digital health solutions.
SaMD & Digital Health Case Study
Explore Freyr’s Regulatory Services for SaMD & Digital Health.
Book a meeting with our experts today
- Schedule a call today
Why Partner with Freyr?
- Proven throughput with 150+ global FDA SaMD approvals, including high-risk and AI-driven software solutions.
- Comprehensive expertise spanning IMDRF/FDA-aligned clinical evaluation, IEC 62304 standard QMS, and cybersecurity compliance.
- Global regulatory playbook enabling seamless market entry across the US, EU, Canada, Australia, and emerging markets.
- Accelerated submission cycles through digital-first documentation frameworks and integrated Regulatory intelligence.
- Trusted by leading MedTech and digital health innovators for scalable, audit-ready Regulatory solutions worldwide.
Frequently Asked Questions
01. What is FDA SaMD, and how is it regulated in the US?
Software as a Medical Device (SaMD) refers to standalone software intended for medical purposes without being part of a physical medical device. In the United States, SaMD is regulated by the FDA, which applies a risk-based framework and requires appropriate premarket submissions such as 510(k), De Novo, or PMA based on intended use.
02. Do all digital health products require FDA approval?
Not all digital health products require FDA approval. Software intended for general wellness or lifestyle purposes may be exempted from regulation. However, digital health solutions that diagnose, treat, monitor, or manage medical conditions are typically subject to FDA oversight and applicable regulatory requirements and SaMD registrations in US.
03. What regulatory pathways are available for FDA Software as a Medical Device (SaMD) in the US?
FDA regulates SaMD through risk-based pathways including the 510(k) notification for devices demonstrating substantial equivalence, the De Novo pathway for novel low- to moderate-risk software without a predicate, and Premarket Approval (PMA) for high-risk SaMD requiring comprehensive clinical evidence. Selecting the appropriate pathway is critical to achieving timely and sustainable U.S. market access.
04. How can a company prepare for FDA submissions for SaMD?
Preparation involves determining the correct product classification, defining an appropriate FDA regulatory strategy, generating and documenting safety and performance evidence, ensuring compliance with quality management system for SaMD and software lifecycle standards, and compiling complete, accurate FDA submission dossiers.
05. What post-market obligations exist for SaMDs and digital health products?
Post-market responsibilities include ongoing monitoring of product performance, timely adverse event reporting, proactive cybersecurity management, controlled software updates, and continued compliance with FDA SaMD Quality System Regulations (QSR) and post-market surveillance requirements.
06. How long does the FDA approval process typically take?
The timeline varies based on the regulatory pathway and product complexity. 510(k) submissions typically take 3–6 months, De Novo 6–12 months, and PMA can take 12–24 months or more.
07. Can Freyr help non-US companies enter the US market?
Yes, our team provides end-to-end regulatory support for non-US digital health and Software as a Medical Device companies, covering SaMD FDA regulatory strategy, premarket submissions, quality and compliance requirements, and ongoing post-market guidance to support successful US market entry and sustained compliance.
